Paratek boosts com­mer­cial port­fo­lio in move to buy Opti­nose and its nasal spray

Paratek Phar­ma­ceu­ti­cals is ex­pand­ing be­yond an­tibi­otics and in­fec­tious dis­ease by pay­ing up to $330 mil­lion to ac­quire Opti­nose and its drug-de­vice com­bi­na­tion for chron­ic rhi­nos­i­nusi­tis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER